Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Change in Acquisitions & Divestments: 2015-2025

Historic Change in Acquisitions & Divestments for CytomX Therapeutics (CTMX) over the last 9 years, with Sep 2025 value amounting to $20.0 million.

  • CytomX Therapeutics' Change in Acquisitions & Divestments fell 34.43% to $20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $168.0 million, marking a year-over-year decrease of 46.75%. This contributed to the annual value of $255.5 million for FY2024, which is 7.09% down from last year.
  • Latest data reveals that CytomX Therapeutics reported Change in Acquisitions & Divestments of $20.0 million as of Q3 2025, which was down 38.46% from $32.5 million recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Change in Acquisitions & Divestments registered a high of $125.0 million during Q4 2023, and its lowest value of $10.0 million during Q3 2021.
  • Moreover, its 3-year median value for Change in Acquisitions & Divestments was $50.2 million (2023), whereas its average is $63.4 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first tumbled by 81.82% in 2021, then grew by 25.00% in 2023.
  • Quarterly analysis of 5 years shows CytomX Therapeutics' Change in Acquisitions & Divestments stood at $10.0 million in 2021, then reached $100.0 million in 2022, then grew by 25.00% to $125.0 million in 2023, then crashed by 48.00% to $65.0 million in 2024, then crashed by 34.43% to $20.0 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $20.0 million for Q3 2025, versus $32.5 million for Q2 2025 and $50.5 million for Q1 2025.